Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

Evaluating short-course ABVD chemotherapy in patients with early-stage Hodgkin lymphoma

Posted by on Sep 28, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of short-course (2 cycles) ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy with interim PET scanning in previously untreated patients with early-stage (stage 1 – 2) Hodgkin’s lymphoma (HL). This study concluded that short-course ABVD was effective in the majority of...

Read More

Evaluating BendaEAM chemotherapy before stem cell transplantation for relapsed lymphoma

Posted by on Sep 28, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the BendaEAM (bendamustine, etoposide, cytarabine, melphalan) in patients with lymphoma undergoing autologous stem cell transplantation (auto-SCT). This study concluded that BendaEAM is a feasible option for these patients, with minimal side effects. Some background High-dose...

Read More

Evaluating brentuximab vedotin in high-risk patients with relapsed or refractory HL

Posted by on Sep 21, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of brentuximab vedotin (Adcetris) in patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that brentuximab vedotin was effective and well-tolerated in these high-risk patients. Some background The...

Read More

The effects of brentuximab vedotin in patients with unresponsive Hodgkin Lymphoma

Posted by on Sep 18, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effects of brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma after stem cell transplant. Brentuximab vedotin appeared to be effective and safe for these patients. Some background Many patients with Hodgkin lymphoma (HL) are cured by standard therapies. However, some patients lose...

Read More

Chemoradiation and hypothyroidism in patients with Hodgkin Lymphoma.

Posted by on Sep 15, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the development of hypothyroidism in patients with Hodgkin lymphoma after chemoradiation therapy. Patients were more likely to develop hypothyroidism after intensity modulated radiation therapy than after 3-dimensional conformal radiation therapy. Some background Patients with Hodgkin lymphoma (HL) are commonly...

Read More

“Your Life Depends on Your Own Advocacy”

“Your Life Depends on Your Own Advocacy”

Posted by on Sep 10, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 1 comment

“Always trust your gut. Don’t leave your treatment in the hands of someone that you don’t trust or that does not seem like a team player. Yes, they are all smart—even brilliant—but read, read, read, and question them at every corner and challenge the standard of care. Exercise, healthy eating, learning the ropes of insurance, mediation/prayer...

Read More

Evaluating the risk of developing acute myeloid leukemia or myelodysplastic syndrome after a stem cell transplant

Posted by on Sep 4, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) development in patients with lymphoma and myeloma after an autologous stem cell transplant (autoSCT). This study concluded that this risk is quite high after autoSCT in these patients. Some background AML and MDS are known long-term...

Read More